BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7680282)

  • 1. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
    Schilsky RL; Janisch L; Berezin F; Mick R; Vogelzang NJ; Ratain MJ
    Cancer Res; 1993 Mar; 53(6):1293-6. PubMed ID: 7680282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
    Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
    Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
    Schilsky RL; O'Laughlin K; Ratain MJ
    Cancer Res; 1986 Aug; 46(8):4184-8. PubMed ID: 3731086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
    Noda K; Hirabayashi K; Terashima Y; Ozaki M; Yakushiji M; Hatae M; Kanazawa K
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1285-93. PubMed ID: 9279348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study.
    Speth PA; Kinsella TJ; Belanger K; Klecker RW; Smith R; Rowland JB; Collins JM
    Cancer Res; 1988 May; 48(10):2933-7. PubMed ID: 2965970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
    McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
    Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.
    Remick SC; Benson AB; Weese JL; Willson JK; Ramirez G; Wirtanen GW; Alberti DB; Nieting LM; Tutsch KD; Fischer PH
    Cancer Res; 1989 Nov; 49(22):6437-42. PubMed ID: 2804987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
    Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    Marshall JL; Richmond E; DeLap RJ
    Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
    Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
    Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
    Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
    Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
    Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.